The estimated Net Worth of Lupe M Rivera is at least $523 mil dollars as of 15 August 2011. Lupe Rivera owns over 3,203 units of Exelixis Inc stock worth over $511,802 and over the last 19 years Lupe sold EXEL stock worth over $11,021.
Sign up
Lupe Rivera EXEL stock SEC Form 4 insiders trading
Lupe has made over 8 trades of the Exelixis Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Lupe exercised 3,203 units of EXEL stock worth $85,296 on 15 August 2011.
The largest trade Lupe's ever made was exercising 75,000 units of Exelixis Inc stock on 14 December 2010 worth over $422,250. On average, Lupe trades about 8,139 units every 73 days since 2005. As of 15 August 2011 Lupe still owns at least 19,219 units of Exelixis Inc stock.
You can see the complete history of Lupe Rivera stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Lupe Rivera's mailing address?
Lupe's mailing address filed with the SEC is C/O EXELIXIS, INC., 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRANCISCO, X1, 94083-0511.
Insiders trading at Exelixis Inc
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey y Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
What does Exelixis Inc do?
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
What does Exelixis Inc's logo look like?
Complete history of Lupe Rivera stock trades at Exelixis Inc
Exelixis Inc executives and stock owners
Exelixis Inc executives and other stock owners filed with the SEC include:
-
Dr. Michael M. Morrissey,
CEO, Pres & Director -
Michael Morrissey,
President, Chief Executive Officer, Director -
Gisela Schwab,
President - Product Development and Medical Affairs, Chief Medical Officer -
Christopher J. Senner,
Exec. VP & CFO -
Christopher Senner,
Chief Financial Officer, Executive Vice President -
Jeffrey J. Hessekiel,
Exec. VP, Gen. Counsel & Sec. -
Jeffrey Hessekiel,
Executive Vice President, General Counsel -
Patrick J. Haley M.B.A., MBA,
Exec. VP of Commercial -
Peter Lamb,
Executive Vice President - Scientific Strategy, Chief Scientific Officer -
Stelios Papadopoulos,
Independent Chairman of the Board, Co-Founder -
Charles Cohen,
Independent Director -
Jack Wyszomierski,
Independent Director -
George Poste,
Independent Director -
Vincent Marchesi,
Independent Director -
Julie Smith,
Independent Director -
Alan Garber,
Independent Director -
Maria Freire,
Independent Director -
Carl Feldbaum,
Independent Director -
Lance Willsey,
Independent Director -
Dr. Stelios Papadopoulos Ph.D.,
Co-Founder & Independent Chairman -
Patrick Haley,
Executive Vice President - Commercial -
Laura Dillard,
Exec. VP of HR -
Gregg Bernier,
VP of Marketing -
Susan T. Hubbard,
Exec. VP of Public Affairs & Investor Relations -
Dr. Peter Lamb,
Exec. VP of Scientific Strategy & Chief Scientific Officer -
Dr. Dana T. Aftab,
Exec. VP of Bus. Operations -
George A Scangos,
Director -
Dana Aftab,
CSO/EVP Disc & Trans Research -
Mary C Beckerle,
Director -
David Edward Caligan Partne...,
-
Sue Gail Eckhardt,
Director -
Bob Oliver,
Director -
Tomas J. Heyman,
Director -
Jacqueline Wright,
Director -
Pamela A Simonton,
VP, Corp Tech Development -
Frank Karbe,
Senior VP & CFO -
Deborah Burke,
SVP & Chief Financial Officer -
Jeffrey Latts,
Sr VP, Chief Medical Officer -
Peter Stalder,
Director -
Jason S Fisherman,
Director -
Kristine M Ball,
Controller & Interim CFO -
Frank Mccormick,
Director -
Steven P James,
Sr VP, Commercial Ops -
Jane M Green,
VP, Corp Communications -
Glen Y Sato,
CFO Sec and General Counsel -
Jean Francois Formela,
Director -
Lupe M Rivera,
VP, HUMAN RESOURCES -
Frances K Heller,
EVP, Business Development -
Ian D Malcolm,
VP, STRATEGIC MARKETING -
Christoph Pereira,
VP, Legal Affairs & Secretary -
J. Scott Garland,
EVP & Chief Commerical Officer -
Gregory Plowman,
Sr VP, Research -
Geoffrey M Duyk,
Pres R&D & Chief Sc Off -
Vicki L Goodman,
EVP, Prod Dev & Med Aff &CMO -
Amy C. Peterson,
EVP Prod Dev & Med Aff & CMO